Published in Invest Ophthalmol Vis Sci on May 31, 2012
Corneal nerves: structure, contents and function. Exp Eye Res (2003) 4.21
Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol (2007) 3.96
The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea (1998) 2.86
Endogenous opioids: biology and function. Annu Rev Neurosci (1984) 2.54
An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci (2010) 2.29
Neural regulation of lacrimal gland secretory processes: relevance in dry eye diseases. Prog Retin Eye Res (2009) 2.04
The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res (2004) 1.88
The repeatability of clinical measurements of dry eye. Cornea (2004) 1.84
A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci (2002) 1.73
Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J (2000) 1.70
Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res (2004) 1.61
The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther (1967) 1.59
The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci (2005) 1.55
Tear dynamics and dry eye. Prog Retin Eye Res (1998) 1.50
Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci (2001) 1.38
Schirmer's test. A closer look. Arch Ophthalmol (1983) 1.23
Prevalence of dry eye disease in an elderly Korean population. Arch Ophthalmol (2011) 1.16
Cold-sensitive corneal afferents respond to a variety of ocular stimuli central to tear production: implications for dry eye disease. Invest Ophthalmol Vis Sci (2010) 1.10
Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. Invest Ophthalmol Vis Sci (2003) 1.06
Keratoconjunctivitis sicca and corneal ulcers. Cornea (1990) 1.05
Schirmer test. I. A review. Optom Vis Sci (1993) 1.03
D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board. Invest Ophthalmol Vis Sci (2005) 0.94
Peptidergic innervation of the rat cornea. Exp Eye Res (1998) 0.93
Tear film and ocular surface tests in animal models of dry eye: uses and limitations. Exp Eye Res (2004) 0.92
Delayed wound closure and phenotypic changes in corneal epithelium of the spontaneously diabetic Goto-Kakizaki rat. Invest Ophthalmol Vis Sci (2007) 0.91
Presence of nerves and their receptors in mouse and human conjunctival goblet cells. Invest Ophthalmol Vis Sci (2001) 0.91
Exposure to a dry environment induces strain-specific responses in mice. Exp Eye Res (2007) 0.90
Tear fluid influence on the ocular surface. Adv Exp Med Biol (1998) 0.90
Opioid modulation of magnocellular neurosecretory cell activity. Neurosci Res (2000) 0.89
Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol (2009) 0.88
A simple approach to the repeatability of the Schirmer test without anesthesia: eyes open or closed? Cornea (2007) 0.86
Nucleotides in ocular secretions: their role in ocular physiology. Pharmacol Ther (2008) 0.85
The reproducibility of the Schirmer test. Korean J Ophthalmol (1988) 0.84
Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye. Arch Ophthalmol (2009) 0.83
Transplantation of newborn lacrimal gland cells in a rat model of reduced tear secretion. Isr Med Assoc J (2007) 0.82
Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
Immunohistochemical localization of delta opioid receptors in peripheral tissues. J Comp Neurol (1999) 0.81
The autocrine derivation of the opioid growth factor, [Met5]-enkephalin, in ocular surface epithelium. Brain Res (1998) 0.80
The Charles Prentice award lecture 1989: the physiology of tears. Optom Vis Sci (1990) 0.79
Proenkephalin A derivatives in lacrimal gland: occurrence and regulation of lacrimal function. Exp Eye Res (1992) 0.79
Hydrolysis of enkephalins in homogenates of anterior segment tissues of the albino rabbit eye. Invest Ophthalmol Vis Sci (1986) 0.78
Inhibition of stimulated lacrimal secretion by [D-Ala2]Met-enkephalinamide. Am J Physiol (1989) 0.78
Conjunctival nerve pathology in multiple endocrine neoplasia. A case report. Acta Ophthalmol (Copenh) (1987) 0.77
A parasympathetic ganglion innervating the harderian gland and lacrimal gland of the musk shrew (Suncus murinus): fluorescent tracing and immunohistochemical studies. Exp Anim (1999) 0.77
Co-existence of prodynorphin--opioid peptides and substance P in primary sensory afferents of guinea-pigs. NIDA Res Monogr (1986) 0.77
Nerve fibers showing immunoreactivities for proenkephalin A-derived peptides in the lacrimal glands of the guinea pig. Graefes Arch Clin Exp Ophthalmol (1989) 0.76
Gi2 and Gi3 couple met-enkephalin to inhibition of lacrimal secretion. Invest Ophthalmol Vis Sci (1998) 0.76
As Good as it Gets? A Life Course Perspective on Marital Quality. Soc Forces (2005) 2.49
Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ (2007) 1.99
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev (2002) 1.71
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) (2011) 1.47
Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) (2011) 1.44
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med (Maywood) (2012) 1.39
Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Exp Biol Med (Maywood) (2010) 1.38
The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell (2008) 1.25
Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes (2002) 1.10
Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol (2007) 1.01
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol (2009) 0.98
Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res (2009) 0.97
The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res (2007) 0.96
Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther (2007) 0.95
Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats. Diabetes (2006) 0.94
Opioids and the apoptotic pathway in human cancer cells. Neuropeptides (2003) 0.93
Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) (2008) 0.93
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2005) 0.93
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol (2009) 0.92
Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. Anat Rec A Discov Mol Cell Evol Biol (2005) 0.91
Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res (2003) 0.91
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs (2004) 0.90
Opioids and differentiation in human cancer cells. Neuropeptides (2005) 0.90
Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Brain Res Bull (2007) 0.89
The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer (2008) 0.89
Differential effects of vascular growth factors on arterial and venous angiogenesis. J Vasc Surg (2002) 0.88
Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol (2009) 0.88
Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. Brain Res Bull (2009) 0.88
Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Exp Eye Res (2009) 0.87
Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood) (2009) 0.86
B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Immunobiology (2010) 0.86
Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Res Bull (2009) 0.85
Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol (2008) 0.84
Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther (2006) 0.84
Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides (2007) 0.84
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2005) 0.83
Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea (2005) 0.83
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis. Brain Res (2012) 0.83
The Health Policy and Legislative Awareness Initiative at the Pennsylvania State University College of Medicine: theory meets practice. Acad Med (2005) 0.83
Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol (2007) 0.83
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea (2006) 0.82
Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol (2004) 0.82
Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
X-linked retinoschisis: novel mutation in the initiation codon of the XLRS1 gene in a large family. Retina (2006) 0.82
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol (2011) 0.82
The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides (2003) 0.81
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) (2009) 0.81
Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol (2006) 0.80
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology (2010) 0.80
Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Exp Biol Med (Maywood) (2013) 0.80
Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis. Invest Ophthalmol Vis Sci (2010) 0.80
Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor. Brain Res Bull (2013) 0.79
Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol (2012) 0.79
Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int J Oncol (2006) 0.79
Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Clin Experiment Ophthalmol (2013) 0.79
Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg (2003) 0.79
Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid (2008) 0.79
Linkage of posterior amorphous corneal dystrophy to chromosome 12q21.33 and exclusion of coding region mutations in KERA, LUM, DCN, and EPYC. Invest Ophthalmol Vis Sci (2010) 0.79
Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Exp Biol Med (Maywood) (2013) 0.79
Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr Eye Res (2003) 0.78
Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone. Arch Ophthalmol (2008) 0.78
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Invest New Drugs (2012) 0.77
Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2010) 0.77
Gene expression of OGFr in the developing and adult rat brain and cerebellum. Brain Res Bull (2004) 0.77
Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability. J Clin Psychopharmacol (2015) 0.77
Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis. Brain Res Bull (2012) 0.77
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) (2013) 0.76
Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol (2011) 0.76
Failure of radiation therapy in orbital xanthogranuloma. Ophthal Plast Reconstr Surg (2010) 0.75
Targeting opioid signaling in Crohn's disease: new therapeutic pathways. Expert Rev Gastroenterol Hepatol (2011) 0.75